Your browser doesn't support javascript.
loading
Vactosertib, TGF-ß receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer.
Lee, Ji Eun; Lee, Pureunchowon; Yoon, Young-Chan; Han, Beom Seok; Ko, Soyeon; Park, Min Seok; Lee, Yun Ji; Kim, Sang Eun; Cho, Ye Jin; Lim, Joo Han; Ryu, Ji-Kan; Shim, Soyeon; Kim, Dae-Kee; Jung, Kyung Hee; Hong, Soon-Sun.
Afiliação
  • Lee JE; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Lee P; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Yoon YC; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Han BS; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Ko S; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Park MS; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Lee YJ; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Kim SE; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Cho YJ; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Lim JH; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Ryu JK; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
  • Shim S; Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul 03760, Republic of Korea.
  • Kim DK; Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul 03760, Republic of Korea.
  • Jung KH; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea. Electronic address: inhafuture@gmail.com.
  • Hong SS; Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea. Electronic address: hongs@inha.ac.kr.
Biomed Pharmacother ; 162: 114716, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37086509

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2023 Tipo de documento: Article País de publicação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2023 Tipo de documento: Article País de publicação: França